• Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 11.50
▲ +0.75 (6.98%)

This chart shows the closing price for GDR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New genedrive Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GDR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GDR

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for genedrive in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 11.50.

This chart shows the closing price for GDR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in genedrive. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/3/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/17/2021Peel HuntReiterated RatingUnder Review
2/17/2021Peel HuntReiterated RatingUnder Review
7/10/2020Peel HuntReiterated RatingBuy
7/10/2020FinnCapReiterated RatingCorporate
7/2/2020Peel HuntReiterated RatingBuy
6/17/2020Peel HuntReiterated RatingBuy
6/17/2020FinnCapReiterated RatingCorporate
6/3/2020Peel HuntReiterated RatingBuy
5/22/2020FinnCapReiterated RatingCorporate
5/1/2020Peel HuntReiterated RatingBuy
4/20/2020Peel HuntReiterated RatingBuy
4/7/2020Peel HuntReiterated RatingBuy
3/25/2020Peel HuntReiterated RatingBuy
3/5/2020Peel HuntReiterated RatingBuy
2/4/2020Peel HuntReiterated RatingBuy
1/10/2020Peel HuntReiterated RatingBuy
12/3/2019Peel HuntReiterated RatingBuy
11/18/2019Peel HuntReiterated RatingBuy
11/4/2019Peel HuntReiterated RatingBuy
10/3/2019Peel HuntReiterated RatingBuy
9/2/2019Peel HuntReiterated RatingBuy
8/1/2019Peel HuntReiterated RatingBuy
7/18/2019Peel HuntReiterated RatingBuy
7/9/2019Peel HuntReiterated RatingUnder Review
7/3/2019Peel HuntReiterated RatingBuy
6/4/2019Peel HuntReiterated RatingBuy
5/2/2019Peel HuntReiterated RatingBuy
3/28/2019Peel HuntReiterated RatingBuy
2/1/2019Peel HuntReiterated RatingUnder Review
1/15/2019Peel HuntReiterated RatingUnder Review
11/1/2018Peel HuntReiterated RatingBuy
10/3/2018Peel HuntReiterated RatingBuy
9/4/2018Peel HuntReiterated RatingBuy
8/8/2018Peel HuntReiterated RatingBuy
8/1/2018Peel HuntReiterated RatingBuy
7/13/2018Peel HuntReiterated RatingBuy
7/3/2018Peel HuntReiterated RatingBuy
6/20/2018Peel HuntReiterated RatingBuy
5/31/2018Peel HuntReiterated RatingBuy
5/15/2018Peel HuntReiterated RatingBuy
4/10/2018Peel HuntReiterated RatingBuyGBX 152
4/3/2018Peel HuntReiterated RatingBuyGBX 152
3/27/2018Peel HuntReiterated RatingBuyGBX 152
3/20/2018Peel HuntReiterated RatingBuyGBX 152
3/13/2018Peel HuntReiterated RatingBuyGBX 152
2/27/2018Peel HuntBoost TargetBuyGBX 150 ➝ GBX 152
2/1/2018Peel HuntReiterated RatingBuyGBX 150
11/14/2017Peel HuntReiterated RatingBuyGBX 150
10/25/2017Peel HuntInitiated CoverageBuyGBX 150
(Data available from 10/3/2017 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/7/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/6/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/6/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/5/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/5/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/4/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/3/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/3/2022

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
genedrive logo
genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. The company provides Genedrive, a patented small polymerase chain reaction, which enables rapid nucleic acid amplification and detection from various sample types, including plasma, sputum, and buccal swabs. Its Genedrive platform offers Genedrive HCV ID Kit, a qualitative molecular solution for Hepatitis C Virus testing; Genedrive BioPlex for the rapid determination of military biothreats from pathogens; Genedrive MT-RNR1-ID Kit, a rapid genetic test in an emergency neonatal care setting; and Genedrive Connect app, an android-based mobile app that allows added data management flexibility and results transmission. The company serves biotechnology and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally. It has a collaboration agreement with Beckman Coulter Life Sciences to automate the laboratory PCR testing process for COVID-19. The company was formerly known as Epistem Holdings Plc and changed its name to genedrive plc in July 2016. genedrive plc was founded in 2000 and is headquartered in Manchester, the United Kingdom.
Read More

Today's Range

Now: GBX 11.50
Low: 10.56
High: 11.69

50 Day Range

MA: GBX 15.65
Low: 11
High: 19.90

52 Week Range

Now: GBX 11.50
Low: 10
High: 82

Volume

341,937 shs

Average Volume

2,113,097 shs

Market Capitalization

£10.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of genedrive?

The following sell-side analysts have issued research reports on genedrive in the last twelve months:
View the latest analyst ratings for GDR.

What is the current price target for genedrive?

0 Wall Street analysts have set twelve-month price targets for genedrive in the last year. has the lowest price target set, forecasting a price of £100,000 for genedrive in the next year.
View the latest price targets for GDR.

What is the current consensus analyst rating for genedrive?

genedrive currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for GDR.

What other companies compete with genedrive?

How do I contact genedrive's investor relations team?

genedrive's physical mailing address is 48 Grafton Street, MANCHESTER, M13 9XX, United Kingdom. The company's listed phone number is +44-161-9890245. The official website for genedrive is www.genedriveplc.com. Learn More about contacing genedrive investor relations.